Document is current
Any future updates will be listed below
-
Authors
Aguero, Cinthya
Dhaynaut, Maeva
Normandin, Marc D.
Amaral, Ana C.
Guehl, Nicolas J.
Neelamegam, Ramesh
Marquie, Marta
Johnson, Keith A.
El Fakhri, Georges
Frosch, Matthew P.
Gomez-Isla, Teresa http://orcid.org/0000-0002-7977-2075
-
Funding
Funding for this research was provided by:
National Institutes of Health (U01NS086659, R01MH100350, AG005134, AG036694, AG005134, AG005134, AG061206)
- License Information
-
More Information
Article History
Received: 21 February 2019
Accepted: 23 February 2019
First Online: 11 March 2019
Ethics approval and consent to participate
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments.
: Informed consent was obtained from all individual participants included in the study and according to institutional procedures for autopsy consents for post-mortem tissue.
: Cinthya Agüero received research funding from the International Health Central America Institute, San Jose, Costa Rica.Marc D. Normandin received research funding from NIH National Institute of Neurological Disorders and Stroke (U01NS086659) and NIH National Institute of Mental Health (R01MH100350).Keith A. Johnson received research funding from NIH (grants R01 EB014894, R21 AG038994, R01 AG026484, R01 AG034556, P50 AG00513421, U19 AG10483, P01 AG036694, R13 AG042201174210, R01 AG027435 and R01 AG037497) and the Alzheimer’s Association (ZEN-10-174,210 K). Keith A. Johnson has served as paid consultant for Bayer, GE Healthcare, Janssen Alzheimer’s Immunotherapy, Siemens Medical Solutions, Genzyme, Novartis, Biogen, Roche, ISIS Pharma, AZTherapy, GEHC, Lundberg, and Abbvie. He is a site co-investigator for Lilly/Avid, Janssen Immunotherapy and Pfizer.Matthew P. Frosch received research funding from the Massachusetts Alzheimer’s Disease Research Center (NIH AG005134).Teresa Gómez-Isla received research funding from NIH National Institute on Aging (AG005134, AG036694 and AG061206). Teresa Gómez-Isla participated as speaker in an Eli Lilly and Company sponsored educational symposium and serves in an Eli Lilly Data Monitoring Committee. Eli Lilly and Company owns Avid, the company that created AV-1451, one of the PET compounds used in this study.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
